Chronic Rhinosinusitis with Polyps and Comorbid Asthma: Results of Reslizumab Treatment

1 Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, et al. Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. https://doi.org/10.1016/j.jaci.2013.02.036 PMid:23587334 Search in Google Scholar

2 Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449-56.e4. https://doi.org/10.1016/j.jaci.2015.12.1324 PMid:26949058 Search in Google Scholar

3 Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl 29):1-464. https://doi.org/10.4193/rhin20.600 PMid:32077450 Search in Google Scholar

4 Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107(1):73-80. https://doi.org/10.1067/mai.2001.111593 PMid:11149994 Search in Google Scholar

5 Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2019;7(2):589-96.e3. https://doi.org/10.1016/j.jaip.2018.08.021 PMid:30193936 Search in Google Scholar

6 Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016;6(4):373-7. https://doi.org/10.1002/alr.21674 PMid:26678021 Search in Google Scholar

7 Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565-72. https://doi.org/10.1016/j.jaip.2016.04.012 PMid:27393770 Search in Google Scholar

8 Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N. Rhinosinusitis and asthma: A link for asthma severity. Curr Allergy Asthma Rep. 2010;10(3):194-201. https://doi.org/10.1007/s11882-010-0096-0 PMid:20424997 Search in Google Scholar

9 Huang CC, Wang CH, Fu CH, Huang CC, Chang PH, Chen IW, et al. The link between chronic rhinosinusitis and asthma: A questionnaire-based study. Medicine (Baltimore). 2016;95(31):e4294. https://doi.org/10.1097/md.0000000000004294 PMid:27495032 Search in Google Scholar

10 Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28(3):192-8. https://doi.org/10.2500/ajra.2014.28.4033 PMid:24980230 Search in Google Scholar

11 Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716-25. https://doi.org/10.1038/nm.2678 PMid:22561835 Search in Google Scholar

12 Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global Strategy for Asthma Management and Prevention: GINA executive summary. Eur Respir J. 2008;31:143-78. https://doi.org/10.1183/09031936.00138707 Search in Google Scholar

13 Koennecke M, Klimek L, Mullol J, Gevaert P, Wollenderg B. Subtyping of polyposis nasi: Phenotypes, endotypes and comorbidities. Allergo J Int. 2018;27(2):56-65. https://doi.org/10.1007/s40629-017-0048-5 PMid:29564208 Search in Google Scholar

14 Corren J. New targeted therapies for uncontrolled asthma. J Allergy Clin Immunol Pract. 2019;7(5):1394-403. https://doi.org/10.1016/j.jaip.2019.03.022 PMid:31076057 Search in Google Scholar

15 De Filippo M, Votto M, Licari A, Pagella F, Benazzo M, Ciprandi G, et al. Novel therapeutic approaches targeting endotypes of severe airway disease. Expert Rev Respir Med. 2021;15(10):1303-16. https://doi.org/10.1080/17476348.2021.1937132 PMid:34056983 Search in Google Scholar

16 Wu D, Bleier BS, Li L, Zhan X, Zhang L, Wei Y, et al. Clinical phenotypes of nasal polyps and comorbid asthma based on cluster analysis of disease history. J Allergy Clin Immunol Pract. 2018;6(4):1297-305.e1 https://doi.org/10.1016/j.jaip.2017.09.020 PMid:29100865 Search in Google Scholar

17 Fokkens WJ, Lund V, Bachert C, Mullol J, Bousquet J, Canonica GW, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312-9. https://doi.org/10.1111/all.13875 PMid:31090937 Search in Google Scholar

18 Kariyawasam HH, James LK, Gane SB. Dupilumab: Clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020;14:1757-69. https://doi.org/10.2147/dddt.s243053 PMid:32440101 Search in Google Scholar

19 Boiko NV, Lodochkina OE, Kit MM, Kuleshova VG, Nedashkovskaya NG. Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma. Vestn Otorinolaringol. 2021;86(2):43-8. https://doi.org/10.17116/otorino20218602143 PMid:33929151 Search in Google Scholar

20 Koski RR, Hill L, Taavola K. Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps. J Pharm Technol. 2022;38(5):289-96. https://doi.org/10.1177/87551225221105749 PMid:36046351 Search in Google Scholar

21 Legrand F, Klion AD. Biologic therapies targeting eosinophils: Current status and future prospects. J Allergy Clin Immunol Pract. 2015;3(2):167-74. https://doi.org/10.1016/j.jaip.2015.01.013 PMid:25754717 Search in Google Scholar

22 Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: A fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046. https://doi.org/10.1183/13993003.01046-2019 PMid:31249014 Search in Google Scholar

23 Gallo S, Russo F, Mozzanica F, Preti A, Bandi F, Costantino C, et al. Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis. Acta Otorhinolaryngol Ital. 2020;40(2):113-21. https://doi.org/10.14639/0392-100X-N0364 PMid:32469005 Search in Google Scholar

24 Matsunaga NY, Ribeiro MA, Saad IA, Morcillo AM, Ribeiro JD, Toro AA. Evaluation of quality of life according to asthma control and asthma severity in children and adolescents. J Bras Pneumol. 2015;41(6):502-8. https://doi.org/10.1590/S1806-37562015000000186 PMid:26785958 Search in Google Scholar

25 Máspero J. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: Clinical trial evidence and future prospects. Ther Adv Respir Dis. 2017;11(8):311-25. https://doi.org/10.1177/1753465817717134 PMid:28683596 Search in Google Scholar

26 Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol. 2001;86(5):494-507; quiz 507-8. https://doi.org/10.1016/s1081-1206(10)62896-7 PMid:11379801 Search in Google Scholar

27 Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133-41. https://doi.org/10.1016/j.jaci.2006.05.031 PMid:17088140 Search in Google Scholar

28 Boiko NV, Kim AS, Stagnieva IV, Simbirtsev AS. Proinflammatory cytokine content in the saliva of children suffering from chronic tonsillitis. Vestn Otorinolaringol. 2019;84(3):26-31. https://doi.org/10.17116/otorino20198403126 PMid:31486423 Search in Google Scholar

29 Wu Q, Zhang Y, Kong W, Wang X, Yuan L, Zheng R, et al. Which is the best biologic for nasal polyps: Dupilumab, omalizumab, or mepolizumab? A network meta-analysis. Int Arch Allergy Immunol. 2022;183(3):279-88. https://doi.org/10.1159/000519228 PMid:34607329 Search in Google Scholar